Novo Nordisk A/S (NVO)
59.86
+1.05
(+1.79%)
USD |
NYSE |
Jan 12, 16:00
60.02
+0.16
(+0.27%)
Pre-Market: 06:53
Novo Nordisk Research and Development Expense (Quarterly): 2.410B for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Ascendis Pharma A/S | 76.00M |
| Evaxion AS | 2.158M |
| Regeneron Pharmaceuticals, Inc. | 1.338B |
| Omeros Corp. | 15.76M |
| Viking Therapeutics, Inc. | 89.95M |